NFE2L2 and prostate carcinoma: Additionally, complementary studies in TRAMP-C1 prostate cancer models confirm NFE2L2 reactivation using DNMT inhibitor 5-aza-2′-deoxycytidine and histone deacetylase inhibitor Trichostatin A [139,140].